We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Allergy Therapeutics Plc | LSE:AGY | London | Ordinary Share | GB00B02LCQ05 | ORD 0.1P |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 0.00 | 0.00% | 2.85 | 515,871 | 08:00:00 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 2.80 | 2.90 | 2.85 | 2.85 | 2.85 | |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 59.59M | -43.07M | -0.0090 | -3.17 | 135.84M |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| 16:18:46 | O | 34,232 | 2.803 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 03/4/2024 | 07:00 | UK RNS | Allergy Therapeutics PLC Director Resignation |
| 27/3/2024 | 16:13 | ALNC |  EARNINGS AND TRADING: Solid State ups outlook; Quartix trading in line |
| 27/3/2024 | 07:00 | UK RNS | Allergy Therapeutics PLC Interim Results for six months ended 31 Dec 2023 |
| 27/3/2024 | 07:00 | UK RNS | Allergy Therapeutics PLC Update on funding |
| 12/3/2024 | 14:06 | ALNC | Allergy Therapeutics starts dosing patients in peanut allergy trial |
| 12/3/2024 | 08:59 | UK RNS | Allergy Therapeutics PLC VLP Peanut PROTECT Trial Update |
| 12/3/2024 | 07:00 | UK RNS | Allergy Therapeutics PLC VLP Peanut PROTECT Trial Update |
| 11/3/2024 | 07:00 | UK RNS | Allergy Therapeutics PLC Appointment of Shaun Furlong to Board of Directors |
| 08/3/2024 | 13:49 | UK RNS | Allergy Therapeutics PLC Result of AGM |
| 14/2/2024 | 10:22 | ALNC | Allergy Therapeutics forecasts revenue drop but trials going well |
Allergy Therapeutics (AGY) Share Charts1 Year Allergy Therapeutics Chart |
|
1 Month Allergy Therapeutics Chart |
Intraday Allergy Therapeutics Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 18/4/2024 | 10:41 | Allergy Therapeutics - AGY - | 4,884 |
| 07/5/2022 | 15:09 | PEANUT PEANUT PEANUT ALLERGY COMPLETE PREVENTION | 1 |
| 06/5/2022 | 11:08 | Allergy Therapeutics | - |
| 26/5/2021 | 11:10 | Argosy Minerals: Aussie Diamond hunter in SoAfrica | 9 |
| 14/7/2016 | 21:04 | Mike Mitchell Panmure Gordon who covers Allergy Therapeutics PLC (LON:AGY) | 1 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|---|---|---|---|
| 15:18:47 | 2.80 | 34,232 | 959.52 | O |
| 15:10:04 | 2.82 | 130,000 | 3,668.60 | O |
| 14:42:10 | 2.89 | 50 | 1.45 | O |
| 14:41:10 | 2.89 | 8,512 | 246.00 | O |
| 14:40:25 | 2.89 | 50 | 1.45 | O |
| Top Posts |
|---|
Posted at 26/4/2024 09:20 by Allergy Therapeutics Daily Update Allergy Therapeutics Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker AGY. The last closing price for Allergy Therapeutics was 2.85p.Allergy Therapeutics currently has 4,766,439,938 shares in issue. The market capitalisation of Allergy Therapeutics is £135,843,538. Allergy Therapeutics has a price to earnings ratio (PE ratio) of -3.17. This morning AGY shares opened at 2.85p |
Posted at 15/4/2024 08:40 by jimmyloser Good morning Farmer G.I am sorry but I feel the need to disagree. I believe that AGY have behaved professionally towards stakeholders and that news flow is where it should be.I am also in another share and if you were in there you would have cause to grumble. Not a peep for five months.Patience required here and in abundance.JL |
Posted at 12/4/2024 21:43 by jpuff It says a valued contribution over a five year period when the share price collapsed from 40p to 2p. I guess that I don't get it either! |
Posted at 12/4/2024 19:21 by jimmyloser Hi Farmer G.You know that this is AGY and that means that those of us who bought in for the ride need buckets of patience and the luck of the gods, I suspect a bit like sowing winter barley,I personally anticipate news this side of month end though I remain puzzled at the recent dramatic resignation by Mary T.Thoughts? |
Posted at 20/3/2024 22:10 by farmergeorge Are we optimistic about the outlook for AGY - been out of the loop for a while. |
Posted at 13/3/2024 12:31 by vergeltung Coinbase, Jimmy, I am as keen as any of you that AGY should finally escape its period of bad luck (partly caused by atrocious management - but that's a different matter, one Skygem surely must be asking themselves about) and notch up a few clinical achievements. I also agree that the news from the clinic has been good. However:1) I am underwhelmed at the reaction to the success of G306 announced in November (! 4 months ago!!)- which should occasion the start of final MA approvals and possibly of licensing / M&A activity; it raises questions about management competence that nothing seems afoot at all on this, a target the company has been aiming at since its foundation and 2) this recent Peanut announcement - extremely limited exposure with primarily safety objectives and some blood-chemistry. Highly promising though it is, it's all super-preliminary and represents the very start of the process that G306 supposedly represented the end of. I agree with you that there is great upside potential here but weighing on this are a) the issue of rudimentary management competence and b) the future financing needs which might turn out badly for us minor shareholders after resolutions 11-14 passed at the AGM. |
Posted at 12/3/2024 07:42 by coinbase Allergy Therapeutics commences subcutaneous dosing in peanut allergic patients in Phase I/IIa VLP Peanut PROTECT Trial - hXXps://www.londonst |
Posted at 29/12/2023 12:52 by beccasan All correct considerations in prospective terms. Whether the authorities will register the products and whether the share price will rise. It is also true that all this must then be confirmed by the commercial results, because with these results they will pay the debt. And it is precisely on this point that I have the strongest doubts. I don't think the products will bring in revenue. In any case. The reasons are in my previous posts. Only the debt and the problem of who or how to pay it will remain. ML then still has to explain to us how it is possible that he was not able to guarantee the accounting closure of the last FY after 6 months. Not 6 days or 6 weeks, 6 months.... |
Posted at 29/12/2023 11:31 by vergeltung I have not read the details (not sure they will be public) but assuming all the important points to be covered in the press release, I am encouraged by this development.The new financing is best seen as part debt, part equity. AGY is not a good credit risk. Borrowing money at 12% is not expensive (you would not get a loan from an unconnected commercial lender on this interest alone). So the lending requires an equity 'kicker'. The warrants are worth little until the share price approaches 4p. Imagine selling call options on AGY equity with a strike price of 4p (i.e. about 60% out-of-the-money) - what would their price be? However, once the shares go over 4p the warrants boost the return on the lending. If the share price rises to 6p (more than 2x the current price), for example, the return to the lenders is 62% after 12 months. Greedy! But that is a big 'if'. Furthermore, if the warrants are issued they entitle the lenders to buy new shares at 4p - i.e. if all 1bn warrants are exercised the company receives a further £40m in cash. This funding like an optimistic move - much of the lenders' return depends upon the share price going up 60% from now (2.5p) and I am pleased that the insiders here appear to have confidence that this will happen. I do think this fundraise is good for the company and this seems to be the view of the market. |
Posted at 31/7/2023 20:58 by timbo003 AGM ReportToday's AGM was held at the offices of the company’s solicitors, Cooley (UK) which is located at 22 Bishopgate EC2N 4BQ, it took quite a while to gain access due to various security measures, so if you ever visit anyone in that that building make sure you let them know ahead of your arrival. When I arrived I commented to Peter Jensen (PJ) that I had received no information from AJ Bell (where I hold most of my AGY shares) about the meeting and I was only aware of the meeting through holding a small number of shares as certificates which meant I got a notification through snail mail. PJ then introduced me to the company secretary (Karley Cheeseman) who said she would look into the matter, but judging by the low attendance at the meeting (I was the only retail shareholder present) I suspect I was not the only retail shareholder who had not been informed about the meeting. There were three directors present all non-execs: Peter Jensen, Mary Tavener and Anthony Parker (Southern Fox). Apparently Manuel Llobet (CEO) and Simon Shen (ZQ Capital) joined by video link, but I couldn’t see them and they didn’t appear to participate in the proceedings There were only two resolutions put to shareholders on this occasion, the first was to approve the accounts and the second was to approve the remuneration report. Having just perused the section on director’s remuneration I had a question regarding the performance related portion of the director’s remuneration. For the year in question the CEO was paid approximately £664k, which comprised £388k basic and £276k performance related, so I questioned whether there should have been a performance related payment for any of the executive directors given the appalling share price performance last year. PJ responded by saying that financial year 2022 ended in June 2022 and the factory shut down occurred after the end of the financial year 2022, however for the subsequent year the performance related payment for the CEO would be zero. That seemed like a satisfactory response to me, so I voted to approve resolution 1 and 2. PJ then closed the formal meeting and allocated me about 15 minutes to ask questions about the business. Given the time constraint I had questions on just two topics, 1) the background to the shutdown last year and the apparent lack of forward planning and contingency plans 2) the forthcoming open offer to shareholders. Shutdown: I questioned why they hadn’t stockpiled product before the shutdown or put in place other contingency plans. PJ responded by saying that everything they could say on the matter was laid out in the RNS statements dated 6th April 2022, they were not able to expand on that. It was not through choice they shut down when they did, but it was necessary to do so due to regulatory (MHRA) concerns. Fund raise: I commented that now the share price had risen considerably above the proposed 1p open offer price, and then asked whether they would consider modifying the offer to raise the same amount of money but by issuing (for example) half the number of shares at 2p/share. This would be of particular benefit to shareholders who were not able to participate in the forthcoming raise for whatever reason. PJ turned to the Lawyer (Simon from Cooley UK) to answer that one. Apparently it is not possible as legal documents have now been signed by the company and proposed funders regarding the proposals for a raise at 1p/share. PJ then took the opportunity to state that he intended to take up the offer in full with his 300K shares, I responded by saying that I intended to do likewise but with a smaller shareholding and allocation. I then asked for confirmation that there would be no funds raised from new outside investors (i.e. no accompanying placing which may attract short term flippers), PJ confirmed there would be no accompanying placing. I also asked whether ordinary shareholders would be able to apply for additional excess shares in addition to their basic allocation, the answer was no, all shares not taken up in the open offer would be purchased by ZQ Capital who are underwriting the offer. After the meeting had come to an end, Simon (the lawyer) filled in a couple more gaps on the funding: The open offer cannot/will not take place until they have foreign direct investment (FDI) clearance from four Jurisdictions (interestingly the UK is not one of the four). In theory this should be easy (especially considering the nature of AGY’s business), but in practice it is more prolonged and complicated than anticipated. The company will issue RNS statements on this should there be any significant developments on this which could affect timings. |
Posted at 08/12/2022 08:16 by wizzkid211 Allergy Therapeutics Plc (LSE)LSE:AGY Allergy Therapeutics Share News (AGY) 4 Follow AGYBuySell Share Name Share Symbol Market Type Share ISIN Share Description Allergy Therapeutics Plc LSE:AGY London Ordinary Share GB00B02LCQ05 ORD 0.1P Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade 0.00 0.0% 13.25 13.00 13.50 0.00 19:00:00 Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m) Pharmaceuticals & Biotechnology 84.3 3.7 0.5 29.4 85 Alert Allergy Therapeutics PLC Key updates on Grass MATA MPL and VLP Peanut 08/12/2022 7:00am UK Regulatory (RNS & others) Allergy Therapeutics (LSE:AGY) Intraday Stock Chart Thursday 8 December 2022 Click Here for more Allergy Therapeutics Charts. TIDMAGY RNS Number : 9931I Allergy Therapeutics PLC 08 December 2022 Allergy Therapeutics plc ("Allergy Therapeutics", "ATL" or the "Group") Allergy Therapeutics announces key updates on Grass MATA MPL and VLP Peanut clinical programmes Update on production and funding - Innovative short-course grass pollen immunotherapy with best-in-class potential - If successful, Grass MATA MPL will be the first subcutaneous and aluminium -- free short-course allergy immunotherapy approved in the US - Topline safety & efficacy data for Grass MATA MPL expected Q4 2023 - Safety, tolerability and efficacy data for VLP peanut expected 2023 8 December 2022 Allergy Therapeutics (AIM: AGY), the fully integrated commercial biotechnology company specialising in allergy vaccines, today announces that the first subject has been dosed in the pivotal Phase III G306 trial, to evaluate the efficacy and safety of Grass MATA MPL, the Group's short-course subcutaneous allergen-specific immunotherapy (SCIT) candidate, t hat aims to address the cause of symptoms of allergic rhinoconjunctivitis due to grass pollen. Grass MATA MPL incorporates MicroCrystalline Tyrosine ("MCT(R) ") adsorbed allergoids, and the innovative adjuvant Monophosphoryl-lipid A ("MPL"). This innovative technology only requires patients to receive six injections prior to the grass allergy season to be protected. The pivotal Phase III G306 trial is a multi-centre, randomised, parallel group, double-blind, placebo-controlled clinical trial to confirm the efficacy and safety of Grass MATA MPL. The clinical trial will be conducted in the US and Europe at approximately 120 clinical trial sites. Data readout is planned for Q4 2023. Previously announced top-line results from the G309 exploratory field trial showed meaningful and statistically significant reductions in symptoms due to grass pollen allergy and in the use of relief medications after six SCIT injections with Grass MATA MPL during peak grass pollen season. In addition, the first subjects have been screened and are poised to receive the Group's innovative, short-course peanut allergy vaccine candidate, VLP Peanut in the Phase I PROTECT trial. The first-in-human study is evaluating the safety and tolerability of VLP Peanut in healthy and peanut allergic adult subjects and exploring preliminary proof of efficacy. Plans remain on track for data in 2023. Update on production and funding Further to the announcement on the 28(th) October, work is continuing on cost control and tight capital management following the impact of the pause in production. This includes reviewing all funding options and managing the working capital of the Group. Manuel Llobet, CEO of Allergy Therapeutics, commented: " The start of our pivotal Phase III G306 trial investigating the efficacy and safety of our Grass MATA MPL marks the culmination of our efforts to bring this innovative treatment to millions of patients affected by grass allergies in both the US and Europe. We were encouraged by the results of our short-course grass pollen immunotherapy in the highly successful G309 exploratory field trial and look forward to advancing the development of this innovative treatment. The start of the VLP Peanut PROTECT trial is a significant milestone and a testament to the hard work of the Allergy Therapeutics team, developing innovative approaches that have the potential to transform the way we treat and manage allergies." More information about the Phase III G306 Grass MATA MPL trial can be found on ClinicalTrials.gov under the identifier NCT05540717 . About Grass MATA MPL Grass MATA MPL is being developed as a pre-seasonal subcutaneous immunotherapy product for the treatment of allergic rhinitis and/or rhinoconjunctivitis. Grass MATA MPL contains an extract of 13 grass pollens modified with glutaraldehyde to form allergoids that reduces the reactivity with immunoglobulin E (IgE) antibodies without a reduction in other important immunological properties, such as T-cell reactivity. The allergoid is adsorbed to microcrystalline tyrosine as a depot adjuvant system formulation. Monophosphoryl lipid-A (MPL), is included as an adjuvant to increase the immunogenic effect of the immunotherapy and to enhance the switch from an allergen specific helper T-cell Type 2 (Th2) to helper T-cell Type 1 (Th1) like immune response. This announcement contains inside information for the purposes of Article 7 of Regulatory (EU) No596/2014. - ENDS - |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
